Keymed Biosciences Yönetim

Yönetim kriter kontrolleri 2/4

Şu anda CEO hakkında yeterli bilgiye sahip değiliz.

Anahtar bilgiler

Bo Chen

İcra Kurulu Başkanı

CN¥4.8m

Toplam tazminat

CEO maaş yüzdesi	95.9%
CEO görev süresi	3.6yrs
CEO sahipliği	n/a
Yönetim ortalama görev süresi	4.2yrs
Yönetim Kurulu ortalama görev süresi	3.7yrs

Son yönetim güncellemeleri

Recent updates

CEO Tazminat Analizi

Bo Chen'un ücretlendirmesi Keymed Biosciences'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Jun 30 2024	n/a	n/a	-CN¥743m
Mar 31 2024	n/a	n/a	-CN¥551m
Dec 31 2023	CN¥5m	CN¥5m	-CN¥359m
Sep 30 2023	n/a	n/a	-CN¥313m
Jun 30 2023	n/a	n/a	-CN¥267m
Mar 31 2023	n/a	n/a	-CN¥287m
Dec 31 2022	CN¥4m	CN¥4m	-CN¥308m
Sep 30 2022	n/a	n/a	-CN¥281m
Jun 30 2022	n/a	n/a	-CN¥253m
Mar 31 2022	n/a	n/a	-CN¥2b
Dec 31 2021	CN¥4m	CN¥4m	-CN¥4b
Sep 30 2021	n/a	n/a	-CN¥4b
Jun 30 2021	n/a	n/a	-CN¥4b
Mar 31 2021	n/a	n/a	-CN¥3b
Dec 31 2020	CN¥231k	CN¥227k	-CN¥819m
Dec 31 2019	CN¥188k	CN¥183k	-CN¥168m

Tazminat ve Piyasa: Bo 'nin toplam tazminatı ($USD 660.83K ), Hong Kong pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 487.48K ).

Tazminat ve Kazançlar: Bo şirketinin tazminatı, şirket kârsız olduğu sürece artırıldı.

CEO

Bo Chen (49 yo)

3.6yrs

Görev süresi

CN¥4,788,000

Tazminat

Dr. Bo Chen has been executive Director, chairman of Board and chief executive officer at Keymed Biosciences Inc. since April 03, 2021 and served as Director since April 23, 2018 until April 03, 2021. Dr....

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Bo Chen	Executive Chairman & CEO	3.6yrs	CN¥4.79m	Veri yok
Gang Xu	Senior VP & Executive Director	3.6yrs	CN¥1.61m	Veri yok
Changyun Wang	Senior VP & Executive Director	6.5yrs	CN¥2.81m	Veri yok
Qi Chen	Senior VP & Non Executive Director	6.7yrs	CN¥178.00k	Veri yok
Yanrong Zhang	CFO, VP & Joint Company Secretary	4.2yrs	Veri yok	Veri yok
Qian Jia	Senior Vice President	6.7yrs	Veri yok	Veri yok
Pak Yu Tam	Joint Company Secretary	2.7yrs	Veri yok	Veri yok

4.2yrs

Ortalama Görev Süresi

49yo

Ortalama Yaş

Deneyimli Yönetim: 2162 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 4.2 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Bo Chen	Executive Chairman & CEO	6.6yrs	CN¥4.79m	Veri yok
Gang Xu	Senior VP & Executive Director	6.4yrs	CN¥1.61m	Veri yok
Changyun Wang	Senior VP & Executive Director	3.7yrs	CN¥2.81m	Veri yok
Qi Chen	Senior VP & Non Executive Director	6.4yrs	CN¥178.00k	Veri yok
Cheuk Kin Law	Independent Non Executive Director	3.6yrs	CN¥572.00k	Veri yok
Yang Ke	Independent Non Executive Director	3.6yrs	CN¥476.00k	Veri yok
Xiao-Fan Wang	Independent Non-Executive Director	3.6yrs	CN¥476.00k	Veri yok
Yilun Liu	Non Executive Director	3.7yrs	Veri yok	Veri yok
Min Chuan Wang	Non Executive Director	3.7yrs	Veri yok	Veri yok

3.7yrs

Ortalama Görev Süresi

49yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: 2162 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 3.7 yıldır).

Keymed Biosciences Yönetim

Yönetim kriter kontrolleri 2/4

Anahtar bilgiler

Son yönetim güncellemeleri

Keymed Biosciences Inc., Annual General Meeting, Jun 25, 2024

Executive Chairman & CEO recently sold HK$6.1m worth of stock

Less than half of directors are independent

Less than half of directors are independent

Keymed Biosciences Inc. Announces Executive Changes

High number of new and inexperienced directors

Recent updates

Keymed Biosciences Inc. Receives Marketing Approval from National Medical Products Administration for the Treatment of Moderate-To-Severe Atopic Dermatis in Adults

First half 2024 earnings released: CN¥1.29 loss per share (vs CN¥0.18 profit in 1H 2023)

Keymed Biosciences Inc. to Report First Half, 2024 Results on Aug 27, 2024

Keymed Biosciences Inc. Announces Phase III Clinical Trial of Stapokibart Injection for the Treatment of Seasonal Allergic Rhinitis

Full year 2023 earnings released: CN¥1.38 loss per share (vs CN¥1.18 loss in FY 2022)

Keymed Biosciences Inc., Annual General Meeting, Jun 25, 2024

Full year 2023 earnings released: CN¥1.37 loss per share (vs CN¥1.18 loss in FY 2022)

Keymed Biosciences Inc. to Report Fiscal Year 2023 Results on Mar 26, 2024

New minor risk - Share price stability

Keymed Biosciences Inc. Announces Phase III Clinical Trial of Cm310 for the Treatment of Chronic Rhinosinusitis with Nasal Polyps

Keymed Biosciences Inc. Announces New Drug Application of Stapokibart Injection

Keymed Biosciences Inc. Announces the Latest Data from a Phase I Clinical Study of CMG901

Keymed Biosciences Inc. Announces CM310 Phase III Clinical Trial Topline Data Accepted for Poster Presentation at the European Academy of Dermatology and Venereology Congress 2023

Now 21% undervalued

Executive Chairman & CEO recently sold HK$6.1m worth of stock

Now 21% undervalued

Now 22% undervalued

First half 2023 earnings released: EPS: CN¥0.18 (vs CN¥0.021 in 1H 2022)

Keymed Biosciences Inc. to Report First Half, 2023 Results on Aug 24, 2023

Keymed Biosciences Inc. Announces Latest Data from the Phase I Clinical Study of CM313

Keymed Biosciences Inc. Announces Latest Development on Phase III Clinical Trial of CM310 for the Treatment of Moderate to Severe Atopic Dermatitis in Adults

Keymed Biosciences Inc. Announces Latest Results from the Phase Ia Clinical Study of CMG901 at the 2023 ASCO GI CANCERS SYMPOSIUM

Less than half of directors are independent

Keymed Biosciences Inc. Announces Center for Drug Evaluation of the China National Medical Products Administration Granted CMG901 the Breakthrough Therapy Designation for the Treatment of Advanced Gastric and Gastroesophageal Junction

Keymed Biosciences Inc. Announces Center for Drug Evaluation of the National Medical Products Administration Has Granted CMG90

InnoCare Pharma and Keymed Biosciences Jointly Announce Approval of Clinical Trial of CCR8 Monoclonal Antibody CM369

Keymed Biosciences Inc. to Report First Half, 2022 Results on Aug 29, 2022

Keymed Biosciences Inc. Receives Grants from Center for Drug Evaluation of the National Medical Products Administration for CM310

Keymed Biosciences Announces Dosing of First Patient in Phase I Trial of Bispecific Antibody CM350

Less than half of directors are independent

U.S. Food and Drug Administration Grants CMG901 Fast Track Designation as Monotherapy for the Treatment of Unresectable or Metastatic Gastric and Gastroesophageal Junction Cancer

Keymed Biosciences Inc. Announces Phase II Clinical Study of its Self-Developed Class1 Innovative Drug CM310 Recombinant Humanized Monoclonal Antibody Injection

Keymed Biosciences Inc. Announces Executive Changes

High number of new and inexperienced directors

CEO Tazminat Analizi

CEO

Görev süresi

Tazminat

Liderlik Ekibi

Ortalama Görev Süresi

Ortalama Yaş

Yönetim Kurulu Üyeleri

Ortalama Görev Süresi

Ortalama Yaş